What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Buy
75
KYMR Quote, Financials, Valuation and Earnings
Last price:
$46.43
Seasonality move
:
20.91%
Day range:
$44.62 - $46.82
52-week range:
$19.45 - $53.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
61.07x
P/B ratio:
3.85x
Volume:
861.5K
Avg. volume:
956.5K
1-year change:
49.18%
Market cap:
$3B
Revenue:
$47.1M
EPS (TTM):
-$3.10
Analysts' Opinion
-
Consensus RatingKymera Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $60.47, Kymera Therapeutics has an estimated upside of 33.65% from its current price of $46.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $51.00 representing -9.75% downside risk from its current price of $46.47.
Fair Value
-
According to the consensus of 16 analysts, Kymera Therapeutics has 33.65% upside to fair value with a price target of $60.47 per share.
KYMR vs. S&P 500
-
Over the past 5 trading days, Kymera Therapeutics has underperformed the S&P 500 by -1.79% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kymera Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kymera Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Kymera Therapeutics reported revenues of $22.1M.
Earnings Growth
-
Kymera Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kymera Therapeutics reported earnings per share of -$0.82.
Enterprise value:
2.6B
EV / Invested capital:
3.26x
Price / LTM sales:
61.07x
EV / EBIT:
--
EV / Revenue:
43.52x
PEG ratio (5yr expected):
-0.64x
EV / Free cash flow:
-10.68x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-26.04%
Net Income Margin (TTM):
-409.07%
Return On Equity:
-30.8%
Return On Invested Capital:
-30.8%
Operating Margin:
-336.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $46.7M | $79.4M | $58.9M | $10.3M | $22.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$169.6M | -$173.1M | -$278.2M | -$52.9M | -$74.4M | |
| EBITDA | -$155.7M | -$150.2M | -$232.7M | -$47M | -$63.5M | |
| Diluted EPS | -$2.87 | -$2.51 | -$3.10 | -$0.69 | -$0.82 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $340.8M | $431.4M | $411.6M | $537.3M | $501M | |
| Total Assets | $464.6M | $563.1M | $613.9M | $868.3M | $918.3M | |
| Current Liabilities | $110.1M | $88.3M | $61.9M | $56.1M | $59M | |
| Total Liabilities | $189.3M | $134.3M | $151.9M | $157M | $132.1M | |
| Total Equity | $275.2M | $428.7M | $462M | $711.2M | $786.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$156.8M | -$98.4M | -$234.1M | -$39.6M | -$79.2M | |
| Cash From Investing | $19.2M | -$215.3M | -$24.9M | -$330.6M | $48.6M | |
| Cash From Financing | $154M | $356.8M | $255.4M | $353.8M | $258K | |
| Free Cash Flow | -$163.1M | -$136.3M | -$240M | -$47M | -$79.6M | |
KYMR
Sector
Market Cap
$3B
$32.8M
Price % of 52-Week High
87.24%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
-13.83%
-0.74%
1-Year Price Total Return
49.18%
-35.38%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.00
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$0.00
Relative Strength Index (RSI14)
Buy
Level
67.02
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-52.888
50-day SMA
Buy
Level
$0.00
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.7546)
Sell
CA Score
(Annual)
Level (-0.399)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (1.1841)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Stock Forecast FAQ
In the current month, KYMR has received 16 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KYMR average analyst price target in the past 3 months is $60.47.
-
Where Will Kymera Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kymera Therapeutics share price will rise to $60.47 per share over the next 12 months.
-
What Do Analysts Say About Kymera Therapeutics?
Analysts are divided on their view about Kymera Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kymera Therapeutics is a Sell and believe this share price will drop from its current level to $51.00.
-
What Is Kymera Therapeutics's Price Target?
The price target for Kymera Therapeutics over the next 1-year time period is forecast to be $60.47 according to 16 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KYMR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kymera Therapeutics is a Buy. 16 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KYMR?
You can purchase shares of Kymera Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kymera Therapeutics shares.
-
What Is The Kymera Therapeutics Share Price Today?
Kymera Therapeutics was last trading at $46.43 per share. This represents the most recent stock quote for Kymera Therapeutics. Yesterday, Kymera Therapeutics closed at $46.47 per share.
-
How To Buy Kymera Therapeutics Stock Online?
In order to purchase Kymera Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 52x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
76
AVAV alert for Jun 26
AeroVironment [AVAV] is up 21.6% over the past day.
Buy
51
SITM alert for Jun 26
SiTime [SITM] is down 15.62% over the past day.
Buy
54
NGVC alert for Jun 26
Natural Grocers by Vitamin Cottage [NGVC] is down 12.33% over the past day.
